Tucatinib

From WikiMD's Wellness Encyclopedia

(Redirected from Tukysa)

What is Tucatinib?[edit | edit source]

Tucatinib.svg



What are the uses of this medicine?[edit | edit source]

This medicine is used with the medicines trastuzumab and capecitabine to treat adults with:

  • human epidermal growth factor receptor-2 (HER2) positive breast cancer that has spread to other parts of the body such as the brain (metastatic), or that cannot be removed by surgery, and
  • who have received one or more anti-HER2 breast cancer treatments.


How does this medicine work?[edit | edit source]

  • Tucatinib An orally bioavailable inhibitor of the human epidermal growth factor receptor tyrosine kinase ErbB-2 (also called HER2) with potential antineoplastic activity.
  • Tucatinib selectively binds to and inhibits the phosphorylation of ErbB-2, which may prevent the activation of ErbB-2 signal transduction pathways, resulting in growth inhibition and death of ErbB-2-expressing tumor cells.
  • ErbB-2 is overexpressed in a variety of cancers and plays an important role in cellular proliferation and differentiation.


Who Should Not Use this medicine ?[edit | edit source]

  • This medicine have no usage limitations.


What drug interactions can this medicine cause?[edit | edit source]

Avoid concomitant use with :

  • strong CYP3A inducers or moderate CYP2C8 inducers.
  • Strong CYP2C8 Inhibitors
  • CYP3A Substrates
  • P-gp Substrates


Is this medicine FDA approved?[edit | edit source]

  • It was approved for use in the United States in 2020.


How should this medicine be used?[edit | edit source]

Recommended Dosage

  • The recommended dosage of Tukysa is 300 mg taken orally twice daily in combination with trastuzumab and capecitabine until disease progression or unacceptable toxicity.
  • For patients with severe hepatic impairment, the recommended dosage is 200 mg orally twice daily.

Administration

  • Take Tukysa exactly as your healthcare provider tells you.
  • Tukysa is used with the medicines trastuzumab and capecitabine. Your healthcare provider will tell you the dose of trastuzumab and capecitabine you will take and how you will receive them.
  • Take Tukysa 2 times a day, with or without a meal.
  • Take Tukysa about 12 hours apart or at the same times every day.
  • Swallow Tukysa tablets whole. Do not chew, crush, or split Tukysa tablets before swallowing. Do not take Tukysa tablets if they are broken, cracked, or damaged.
  • If you vomit or miss a dose of Tukysa, take your next dose at your regular time.


What are the dosage forms and brand names of this medicine?[edit | edit source]

This medicine is available in fallowing doasage form:

  • As Tablets: 50 mg and 150 mg

This medicine is available in fallowing brand namesː

  • Tukysa


What side effects can this medication cause?[edit | edit source]

Common possible side effects and laboratory abnormalities of this medicine include:

  • diarrhea
  • rash, redness, pain, swelling or blisters on the palms of your hands or soles of your feet
  • nausea
  • tiredness
  • increased liver function blood tests
  • vomiting
  • mouth sores (stomatitis)
  • decreased appetite
  • stomach-area (abdomen) pain
  • headache
  • low red blood cell counts (anemia)
  • rash

Tukysa may cause serious side effects, including:

  • Diarrhea: Diarrhea is common with Tukysa and can sometimes be severe.
  • Liver Problems: Tukysa can cause severe liver problems.


What special precautions should I follow?[edit | edit source]

  • Severe diarrhea, including dehydration, acute kidney injury, and death, has been reported. Administer antidiarrheal treatment as clinically indicated. Interrupt dose, then dose reduce, or permanently discontinue Tukysa based on severity.
  • Severe hepatotoxicity has been reported on Tukysa. Monitor ALT, AST and bilirubin prior to starting Tukysa, every 3 weeks during treatment and as clinically indicated. Interrupt dose, then dose reduce, or permanently discontinue Tukysa based on severity.
  • Tukysa can cause fetal harm. Advise patients of potential risk to a fetus and to use effective contraception.


What to do in case of emergency/overdose?[edit | edit source]

  • In case of overdose, call the poison control helpline of your country. In the United States, call 1-800-222-1222.

Can this medicine be used in pregnancy?[edit | edit source]

  • Tukysa can cause fetal harm when administered to a pregnant woman.
  • There are no available human data on Tukysa use in pregnant women to inform a drug-associated risk.


Can this medicine be used in children?[edit | edit source]

  • The safety and effectiveness of Tukysa in pediatric patients have not been established.


What should I know about storage and disposal of this medication?[edit | edit source]

  • Store at controlled room temperature, 20ºC to 25ºC (68ºF to 77ºF); excursions permitted from 15ºC to 30ºC (59ºF to 86ºF) .
  • Dispense to patient in original container only. Store in original container to protect from moisture.
  • Replace cap securely each time after opening. Do not discard desiccant.
  • Once opened, use within 3 months.
  • Discard any unused tablets 3 months after opening the bottle.


Tucatinib Resources

Contributors: Deepika vegiraju